TECH · Nasdaq · Healthcare
Bio-Techne Corporation (TECH) — Rank #211 by gross profitability (GP/assets 0.31) · ROE 8.6% · Piotroski F-Score 7 / 9.
As-of 2026-10-30 · CIK 0000842023 · all metrics point-in-time as of the filing date.
About
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Show moreShow less
It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- MN
- Filer Category
- Large accelerated filer
- Fiscal Year End
- June 30
- Website
- bio-techne.com
Company Snapshot
P/E and dividend yield are the primary valuation lenses for mature businesses.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
3,000
Industry
Biotechnology
Exchange
Nasdaq
10/11
Flags passed
TECH fails 1 critical flag
Passes 10 of 11 quality flags
- FAILRevenue declining YoY
Revenue contracted year over year
- PASSGross margin holding
- PASSDilution within 2%
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSNo competitive retreat
- PASSSBC not compressing margin
- PASSNo valuation convergence
Strengths Operating leverage expanding
No data Balance sheet — not counted as a pass.
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passDividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).
Profitability
Does it make money well?
Warning: Revenue declining YoY · GP/assets 0.31
Gross profitability (GP / assets)
0.31
Primary signal (Novy-Marx).
3rd of 5 SIC 2836 peers
Return on equity
8.6%
Gross margin
65.8%
3rd of 5 SIC 2836 peers
Revenue growth (YoY)
-0.4%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.2%
Revenue CAGR (5Y)
5.5%
Earnings CAGR (3Y)
-13.9%
FCF CAGR (3Y)
—
Cash Flow Health
Is the cash real?
No warning flags · FCF 45% above net income
Free cash flow
$263.22M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
44.8%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.4%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net cash $265.78M, F-Score 7/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.24
Current ratio
4.55×
3rd of 5 SIC 2836 peers
Quick ratio
2.95×
Net cash
$265.78M
Cash & equivalents minus total debt.
Piotroski F-Score
7 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
No warning flags
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Dividend safety
Composite score
3.0 / 5
Capital allocation quality
Composite score
1.2 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports